Name in SEC filings: Scholar Rock Holding Corp
Source: ORION, orionbiotechai.com/company/SRRK, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/SRRK
SRK-439 · Topline/data readout · second half of 2026
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
Topline/data readoutsecond half of 2026
Stage: Phase 1SEC filing · “Phase 1”
Public float: $2,600,000,000 · as of · SEC filing
A Phase 1 study of SRK-439 in healthy volunteers is currently underway, with topline data anticipated in the second half of 2026.
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| SRK-439Clinical results | second half of 2026“A Phase 1 study of SRK-439 in healthy volunteers is currently underway, with topline data anticipated in the second half of 2026.” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| SRK-439Clinical results | second half of 2026“A Phase 1 study of SRK-439 in healthy volunteers is currently underway, with topline data anticipated in the second half of 2026.” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| SRK-439Clinical results | second half of 2026“A Phase 1 study evaluating SRK-439 in healthy volunteers is underway, with topline data expected in the second half of 2026.” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| SRK-439Clinical results | second half of 2026“A Phase 1 study of SRK-439 in healthy volunteers is currently underway, with topline data anticipated in the second half of 2026.” Filed · 10-K | Still within period As of Oct 19, 2026 |
| SRK-439Clinical results | second half of 2026“A Phase 1 study in healthy volunteers is underway, and topline data are expected in the second half of 2026.” Filed · 10-K | Still within period As of Oct 19, 2026 |
| SRK-439Clinical results | second half of 2026“A Phase 1 study evaluating SRK-439 in healthy volunteers is underway, with topline data expected in the second half of 2026.” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
These dated records retain their original scope and check dates.
Record SRRK-P2 · Clinical results disclosure · Window open
Last checked: .
· Checked by founder · SEC Exhibit 99.1
Stated period: in H2 2026
SRK-439 Phase 1 trial ongoing in healthy volunteers; topline data expected in H2 2026
· Checked by founder · SEC Exhibit 99.1
Stated period: in the second half of 2026
A Phase 1 study evaluating SRK-439 in healthy volunteers is underway, with topline data expected in the second half of 2026.
· Checked by founder · SEC Exhibit 99.1
Stated period: in the second half of 2026
A Phase 1 study evaluating SRK-439 in healthy volunteers is underway, with topline data expected in the second half of 2026.
· Checked by founder · SEC Form 10-Q
Stated period: in the second half of 2026
A Phase 1 study of SRK-439 in healthy volunteers is currently underway, with topline data anticipated in the second half of 2026.
· Checked by founder · Company press release
Stated period: in late 2026
A Phase 1 study evaluating SRK-439 in healthy volunteers is progressing well with topline data anticipated in late 2026.
· Checked by founder · SEC Exhibit 99.1
Stated period: in late 2026
A Phase 1 study evaluating SRK-439 in healthy volunteers is progressing well with topline data anticipated in late 2026.
· Checked by founder · SEC Form 10-Q
Stated period: in the second half of 2026
A Phase 1 study of SRK-439 in healthy volunteers is currently underway, with topline data anticipated in the second half of 2026.
Company release: · Company original
Company release: · Company original
Company press release listing · checked
The initial entry means the earliest wording located within the sources checked; an exhaustive history is not asserted.
Company timing wording is retained. A newer corporate release about another program does not establish a results announcement for this trial.
Additional source review: 2026-10-10. Earlier retained sources were reviewed on 2026-10-09; their original source-check dates and scopes are retained.
The August 6 Form covers the quarter ended June 30, 2026.
SEC filings searched through : and Ex-99.1 1/12, 3/3 (incl. 8-K/A), 5/7, 10-Q 5/7, 8-K and Ex-99.1 8/6 checked against originals. Later SEC filings not searched. Supplement reviewed 2026-10-10: selected 2026-08-06 SEC Form 10-Q timing occurrences. This is not an exhaustive later-filing search.
Company press releases checked : Press releases page 1 checked on 10/9; Oct 8 release is apitegromab MAA, not SRK-439.
Checked by founder: .
· Display rule corrected — equivalent timing phrases (e.g., 'H2 2026' / 'second half of 2026') are now shown as Statement retained. Source quotes and status unchanged. · Equivalent timing notation is compared after normalization. · Founder approved the normalization correction and this exact public line in this chat on 2026-10-09.
· Added previously omitted 2026-08-06 SEC Form 10-Q timing source. · Selected-source supplement following founder review; prior rows retained. · https://www.sec.gov/Archives/edgar/data/1727196/000119312526336732/srrk-20260630.htm
Scholar Rock (SRRK) — SRK-439 · topline data: “in H2 2026” (SEC Exhibit 99.1 2026-01-12); statement retained “in the second half of 2026” (2026-03-03); statement retained “in the second half of 2026” (2026-05-07); statement retained “in the second half of 2026” (2026-05-07); wording changed from “in the second half of 2026” (2026-05-07) and “in the second half of 2026” (2026-05-07) to “in late 2026” (2026-08-06); wording changed from “in the second half of 2026” (2026-05-07) and “in the second half of 2026” (2026-05-07) to “in late 2026” (2026-08-06); statement retained “in the second half of 2026” (2026-08-06). Status Window open, checked 2026-10-10. Sources: https://www.sec.gov/Archives/edgar/data/1727196/000110465926002757/srrk-20260112xex99d1.htm | https://www.sec.gov/Archives/edgar/data/1727196/000110465926022547/srrk-20260303xex99d1.htm | https://www.sec.gov/Archives/edgar/data/1727196/000110465926056655/srrk-20260507xex99d1.htm | https://www.sec.gov/Archives/edgar/data/1727196/000110465926056667/srrk-20260331x10q.htm | https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-reports-second-quarter-2026-financial-results-and | https://www.sec.gov/Archives/edgar/data/1727196/000119312526336715/srrk-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/1727196/000119312526336732/srrk-20260630.htm
A Phase 1 study of SRK-439 in healthy volunteers is currently underway, with topline data anticipated in the second half of 2026.
Suggest an SEC timing statement to add for SRRK. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.
See SRRK in the calendar · Review labels and methodology